ImmuPharma (LSE:IMM) Total Liabilities : £1.55 Mil (As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is ImmuPharma Total Liabilities?

ImmuPharma's Total Liabilities for the quarter that ended in Jun. 2023 was £1.55 Mil.

ImmuPharma's quarterly Total Liabilities increased from Jun. 2022 (£0.86 Mil) to Dec. 2022 (£1.45 Mil) and increased from Dec. 2022 (£1.45 Mil) to Jun. 2023 (£1.55 Mil).

ImmuPharma's annual Total Liabilities increased from Dec. 2020 (£1.26 Mil) to Dec. 2021 (£1.58 Mil) but then declined from Dec. 2021 (£1.58 Mil) to Dec. 2022 (£1.45 Mil).

ImmuPharma Total Liabilities Historical Data

The historical data trend for ImmuPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Total Liabilities Chart

ImmuPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

1.04

0.53

1.26

1.58

1.45

ImmuPharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															1.77	1.58	0.86	1.45	1.55

ImmuPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ImmuPharma's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.451	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.45

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	3.975	-	2.523
	=	1.45

ImmuPharma's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.551	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.55

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	3.288	-	1.737
	=	1.55

ImmuPharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of ImmuPharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuPharma (LSE:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IMM.GB:UK 25I:Germany

Address

One Bartholomew Close, London, GBR, EC1A 7BL

Website

https://www.immupharma.co.uk

ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (LSE:IMM) Headlines

No Headlines